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Gene therapy for the treatment of cystic fibrosis should be a “natural”: Cystic fibrosis (CF) is
a recessive disease associated with loss of function mutations in the CF transmembrane
conductance regulator (CFTR) gene, which has a well-characterized gene product;
heterozygotes, as predicted, appear to be phenotypically perfectly normal; the level of
expression of CFTR in affected cells generally appears to be low; and the dysfunctional
epithelial lining cells in the organ most affected by CF (the lung) are available for direct
vector delivery via topical administration (1). However, despite an impressive amount of
research in this area, there is little evidence to suggest that an effective gene-transfer
approach for the treatment of CF lung disease is imminent. The inability to produce such a
therapy reflects in part the learning curve with respect to vector technology and the failure to
appreciate the capacity of the airway epithelial cells to defend themselves against the
penetration by moieties, including gene-therapy vectors, from the outside world. This
Perspective will focus on the issues that impact on moving this field forward. What is the
target for CF gene therapy in the lung? Cystic fibrosis affects the conducting airways of the
lung and not the alveolar surfaces. The airways in general consist of a “large” airway
(bronchial) region that is lined by a pseudostratified columnar superficial […]
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Gene therapy for the treatment of cystic fibrosis should be
a “natural”: Cystic fibrosis (CF) is a recessive disease asso-
ciated with loss of function mutations in the CF trans-
membrane conductance regulator (CFTR) gene, which
has a well-characterized gene product; heterozygotes, as
predicted, appear to be phenotypically perfectly normal;
the level of expression of CFTR in affected cells generally
appears to be low; and the dysfunctional epithelial lining
cells in the organ most affected by CF (the lung) are avail-
able for direct vector delivery via topical administration
(1). However, despite an impressive amount of research in
this area, there is little evidence to suggest that an effective
gene-transfer approach for the treatment of CF lung dis-
ease is imminent. The inability to produce such a therapy
reflects in part the learning curve with respect to vector
technology and the failure to appreciate the capacity of
the airway epithelial cells to defend themselves against the
penetration by moieties, including gene-therapy vectors,
from the outside world. This Perspective will focus on the
issues that impact on moving this field forward.
What is the target for CF gene therapy in the lung? Cystic fibro-
sis affects the conducting airways of the lung and not the
alveolar surfaces. The airways in general consist of a “large”
airway (bronchial) region that is lined by a pseudostratified
columnar superficial epithelium and contains numerous
submucosal glands, and a “small” airway (bronchiolar)
region that is lined by a simple columnar epithelium and
is devoid of glands. Central issues for CF gene therapy are
which region (large vs. small) and which tissue (superficial
epithelium vs. glands) should be targeted.
Obviously, the answer to this question requires knowl-
edge of the pathogenesis of CF lung disease. As reviewed
earlier in this Perspective series (2, 3), this is a controversial
issue. Although the so-called “isotonic” and “hypotonic”
airway surface liquid theories have different predictions on
the pathogenesis of CF airways infection, both agree that
defects in the superficial epithelium may initiate CF lung
disease. However, studies from other model cell culture sys-
tems, like Calu-3 cells and cultured gland acini (4), predict
that there may be abnormalities in gland volume/compo-
sitional (HCO3–) regulation in CF that may be more impor-
tant in the pathogenesis of CF airways infection. This
debate can also be viewed in the context of the individual
cell types in the airways. Advocates of the importance of the
superficial epithelium in CF pathogenesis likely would
favor targeting the ciliated cell, which clearly exhibits all of
the ion transport functions of CFTR and exhibits abnormal
function in patients with CF (5), whereas advocates of the
importance of the submucosal gland would likely favor tar-
geting the submucosal gland serous cells, which may be the
highest CFTR-expressing cell type in the lung (6).
In the absence of definitive data from model systems,
from an operational point of view probably the best strat-
egy is to examine the sequence of disease in young CF
patients and select the target based on those data. Perhaps
the most relevant observations are that CF infants typical-
ly present clinically with physical and roentgenographic
findings of bronchiolitis, exhibit as their first pulmonary
function abnormality small airways obstruction, and have
evidence from autopsy studies of mucus plugs in small air-
ways. These data suggest that as in other major airway dis-
eases — chronic bronchitis, for example — small airways are
the initial and major site of functional disease (airflow
obstruction) in the CF lung. Therefore, restoration of func-
tion in the superficial epithelium lining small airways
should be clinically beneficial. This reasoning does not dis-
miss expression of abnormal function in proximal CF air-
ways. Indeed, virtually all studies of epithelial dysfunction
in the lung have detected differences in this region, but the
importance of small airways obstruction in the phenotype
of airways disease suggests that selective correction of
epithelial defects in the large airways will not be therapeu-
tically useful. Interestingly, virtually all gene-therapy trials
to date have delivered vectors via the topical route to the
superficial epithelium, but it is not obvious that aerosol
delivery strategies have been optimized for small airway
deposition. Although deposition is difficult in patients
with airways occluded by mucus plugs and infection, it will
be important to develop efficient means to deliver vectors
via aerosol to small airways.
However, it is possible that it may be important to treat
submucosal glands and that we will not be able to devise
strategies to effectively dose CF airways. Therefore, it
would appear prudent to continue efforts to deliver vec-
tors systemically that could access gland regions as well
as the superficial epithelium of occluded airways.
How much gene transfer is enough? A key issue is to dis-
tinguish between the concepts of “level of CFTR trans-
duced/cell” and “percent correction,” denoting the frac-
tion (percentage) of CF cells within an epithelial region
(area) that are “corrected.” With regard to level of trans-
duced CFTR/cell, based on endogenous CFTR expres-
sion data it is likely that the level required for ciliated
cells will be very low whereas the level required for
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serous cells will be higher (4). With regard to percent
correction, initial studies focused on this issue utilized
monolayers of immortalized CF epithelial cells com-
prised of varying percentages of CF cells and CF cells
“corrected” with wild-type CFTR (7). These studies
showed that approximately 6%–10% of the cells within
a monolayer must consist of “corrected” CF cells to
restore normal Cl– transport function.
While informative, the study by Johnson et al. empha-
sizes the importance of both knowledge of the patho-
genesis of CF lung disease and the fidelity of the model
system to the in vivo situation to accurately address this
issue. For example, the epithelial model system used for
these studies comprised a mosaic monolayer epithelium
that was highly connected via gap junctions, utilized
“corrected” CF cells that expressed rather high levels of
CFTR per cell, and focused only on Cl– transport. The
“amplification of correction” (i.e., normalization of func-
tion with correction of a small percentage of epithelial
cells) reported in that study likely reflected the move-
ment of Cl– ions from non-corrected to corrected cells
through gap junctions, with Cl– secretion reflecting exit
through a “lot” of CFTR in a small number of corrected
cells. It is likely that the number of gap junctions per cell
in a well-differentiated epithelium in vivo is less than in
the immortalized airway cells used in this study, and
hence the percentage of cells requiring correction to
restore normal Cl– transport in vivo may well exceed 10%.
The relationship between normalization of function
and percentage of corrected cells within the epithelium
is also quite different if one considers Na+ transport.
Recent data have suggested that lack of CFTR regulation
of Na+ transport rates may be important in the patho-
genesis of CF lung disease and that the relationship
between CFTR and Na+ transport is more “local,” i.e.,
may involve protein–protein interactions confined to
single cells (1). Thus, when abnormal CF Na+ transport
is used as an index of correction, one finds a linear rela-
tionship between the percentage of cells in a monolayer
corrected and the percent normalization of function (8).
Consequently, the simplest strategy to assure efficacy is
to mimic the normal pattern of expression, i.e., there
should be a low level of expression per cell, and virtually
every affected cell (100%) should be corrected. Is there an
acceptable percentage below 100% of cells that
might justify the initiation of a clinical trial? Given
the likely difficulties in achieving gene transfer in
man in vivo compared to any model system, cer-
tainly more than 10% of cells should be transduced
in the most relevant model systems, e.g., studies of
human explants and pertinent animal models in
vivo. Unfortunately, none of the current in vivo model sys-
tems, such as the CF mouse, yield a sufficiently accurate
lung infection phenotype to allow this critical question to
be evaluated in a whole animal system.
Where are we in the clinic? Approximately 20 trials of CF
gene therapy dosing the lung have been completed. These
studies essentially have all been Phase I safety studies that
have delivered both viral and nonviral vectors topically to
the nose and/or lower airways via direct liquid instillation
or via aerosol. With respect to adenoviral vectors, both sin-
gle and multiple dosing studies have been performed.
From these Phase I trials, there has been a wealth of data
produced on the safety aspects of first-generation nonviral
and viral vectors. In brief, there have been no instances of
identification and/or recovery of recombinant viruses from
viral vectors, and relatively few if any DNA/vector-specific
systemic effects resulting from intrapulmonary vector
instillation have been detected. There have been reports of
both inflammatory adverse events and immunologic
responses to vectors. With respect to acute inflammatory
responses, tachykinin-mediated neuroinflammatory
responses in the nasal cavity in response to high-dose ade-
noviral vectors have been reported. A syndrome associated
with acute pulmonary inflammation has also been report-
ed (9). It is not clear what the etiology of this latter syn-
drome may be and whether it reflects, in part, deposition of
vectors on alveolar versus airway surfaces, and/or the
immune status of the patients. An acute, presumably
cytokine-mediated response to liposome-mediated gene
transfer in the lung has also been reported (E. Alton, per-
sonal communication). With respect to more delayed
immunologic responses, rather small increases in adenovi-
ral neutralizing antibody titers have been reported without
an adverse clinical outcome (10). Although the data are
more sparse, few or no inflammatory/immunologic
responses have been reported with the AAV vectors.
With respect to gene-transfer efficiency/efficacy, per-
haps the most quantitative data available are from stud-
ies that have dosed the nasal epithelium. For adenoviral
vectors, initial reports from unblinded studies using
nasal PD protocols that discriminated poorly between
the CF versus normal phenotype indicated functional
correction of CF epithelial Cl– transport (11). Data from
larger, placebo-controlled and blinded studies indicate
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Figure 1
Barriers to vector-mediated gene transfer in WD columnar airway
epithelial cells. The failure of vectors to bind to the apical membrane
of WD cells is depicted on the left cell; the failure of “non-specifi-
cally” bound vectors to internalize is shown on the right cell. The
tight junctions separate the apical cell membrane from the basolat-
eral domain that selectively expresses specific viral receptors, e.g., the
CAR, “housekeeping”/growth receptors, and integrins. WD, well-dif-
ferentiated. CAR, Coxsackie virus and adenovirus receptor.
that topical delivery of adenoviral vector to the nasal
epithelium results in little gene transfer or functional
correction, as measured with a combination of molecu-
lar (PCR) and functional (nasal PD) techniques (12).
Similarly, there is little evidence of significant gene trans-
fer with liposome-mediated gene delivery in the nasal
cavity, using a variety of lipids and plasmid systems. The
data with AAV in the nose are preliminary but also sug-
gest poor efficacy.
Efficacy studies in the lower airways are more difficult to
perform because of the difficulty in defining the precise
sites of vector delivery and the inability to assess gene trans-
fer quantitatively. With respect to adenoviral gene transfer,
PCR assessment of gene transfer has detected wild-type
CFTR transcripts in brushings from dosed CF airways but
there are few quantitative data measuring the percent trans-
duced epithelial cells in the region and no functional (PD)
measurements of correction. With respect to liposomes,
one nicely designed and performed study attempted to
measure functional and molecular correlates of CFTR
expression after aerosolized liposome-plasmid dosing of the
lung. These investigators reported perplexing evidence for
modest correction of Cl- transport, but not Na+ transport
function in the lung, without molecular (PCR) evidence of
gene transfer (E. Alton, personal communication). Finally,
although data from AAV administration to the lung are
preliminary, they appear to show inefficiency as well.
What is the barrier to successful gene delivery? The major
problem confronting CF gene therapy
is the inefficiency of gene transfer.
Whereas studies of inflammation and
immunologic consequences of vector
dosing are important and should be
performed, such studies will not be
fully informative until adequate gene
transfer efficiency is achieved. This will
allow the complex inflammatory/
immunologic picture of expression of
wild-type CFTR in the CF lung to be
investigated properly.
Inefficient gene transfer reflects the
extremely effective adaptations of airway epithelia to pre-
vent the penetration of foreign materials into airway epithe-
lial cells or the interstitium. Airway epithelia create a com-
plex series of barriers to prevent penetration of lumenally
delivered materials, including both viral and non-viral vec-
tors, into the cell or interstitial compartment. In series, these
barriers comprise a well-defined mucus layer that may bind
inhaled vectors and clear them via mucus clearance mech-
anisms, a glycocalyx that may bind vectors and prevent
binding to cell surface receptors, and perhaps most impor-
tantly, an apical cell membrane that is relatively devoid of
viral receptors and growth/tropic receptors that internalize
as part of their biology (Fig. 1). This series of barriers is com-
plemented by epithelial tight junctions that are “moderately
leaky” to ions but quite “tight” for larger solutes, thereby
preventing penetration by current vectors from lumenal
surfaces to the interstitium. Airway cells express most of the
receptors that are used by current viral vectors for
“virus-specific” entry on the basolateral membrane. Recent
reports confirm that specific vector receptors, e.g., the ade-
novirus receptor (13), the AAV receptor (heparan sulfate)
(14), and the VSV receptor (15) are indeed localized to the
basolateral membrane. In addition, most of the house-
keeping/growth/trophic hormone receptors are also locat-
ed basolaterally.
The early studies with model systems that employed
poorly differentiated airway epithelial cells suggested
that gene-transfer efficiency for a variety of vectors
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Figure 2
Strategies to increase adenovirus-mediated
gene-transfer efficiency for well-differenti-
ated columnar airway epithelial cells. 
(a) “Modification of the host.” In this
approach, the tight junctions are rendered
permeable to vectors, which permits
access to “vector-specific” receptors. 
(b) “Modification of the vector.” A repre-
sentative seven-transmembrane (7-TM) G-
protein–receptor is shown that is activat-
ed to internalize via interaction with an
agonist (denoted by purple-filled circle).
Representative (adenovirus) vector is
directed toward an external epitope of the
receptor by bispecific antibodies (bs–Ab).
Upon exposure to agonist, the 7-TM
receptor is sequestered into a clathrin
coated pit, carrying the vector into the cell.
would be high. However, with the advent of the use of
well-differentiated (WD) culture systems, supplemented
by freshly excised organ culture systems, it became clear
that a common theme was emerging: a) that virtually all
vectors (viral and nonviral) did not bind to the apical
(lumenal) surfaces of WD airway epithelial cells; and b)
that apical surfaces of WD airway epithelial cells have a
low basal and stimulated rate of endocytosis (13, 16).
What is the answer to increase efficiency? It is apparent that
novel strategies must be adopted to increase gene-trans-
fer delivery. As mentioned above, strategies that may use
the vascular compartment as a dosing route should be
explored but the difficulties in overcoming the large
number of barriers between the vascular compartment
and airway epithelial cells — endothelial cell, endothelial
cell basement membrane, interstitium, and epithelial
basement membrane — make this route challenging.
With respect to intralumenal dosing of the superficial
epithelium, at least two general strategies can be envi-
sioned to increase gene-transfer efficiency.
In a strategy termed “modification of the host,” it may be
rational to reduce the barrier functions of epithelial tight
junctions so that vectors can penetrate to the basolateral
membrane of target cells that, as indicated above, are nat-
urally rich in viral and other internalizing receptors (Fig.
2). Abrogation of tight junction barrier function can be
achieved by non-specific damage, such as has been demon-
strated with oxidant gases (17) and surface-active adju-
vants, e.g., detergents (18). Such strategies have been shown
to increase gene-transfer efficiency in airways of rodents
dramatically, but it likely will be difficult to titrate down
the dose of an oxidant gas and/or deliver a specific mass of
a detergent safely to make this strategy therapeutic for CF
patients. More specific modifications of tight junctional
permeability through cellular regulatory mechanisms thus
are more appealing. Increasing knowledge of the cellular
regulation of tight junctional permeabilities, including the
interrelationships between the adherens junction and the
tight junction, may make this approach feasible. The ulti-
mate goal is a safe and effective strategy, which depends on:
a) transient, reversible permeabilization of tight junctions;
and b) permeabilization of tight junctions without pro-
ducing inflammation, hence avoiding vascular leak into
the airway lumen and airways irritation.
The alternative approach is to “modify the vector.” The
concept here is to direct a vector to a “target” expressed
on the apical cell membrane that has the capacity to
both bind and internalize a vector. Identification of suit-
able targets in the airway has not been easy because of
the paucity of expressed receptor/membrane proteins on
airway epithelial surfaces that internalize as a function
of their biology. However, there is a class of receptors
that normally mediates acute airway epithelial cell
responses to the lumenal environment, i.e., seven trans-
membrane receptors. Several members of this class are
expressed on the lumen of human airway cells.
Perhaps the most attractive target from the point of view
of the level and extent of expression in the airways is the
extracellular ATP/UTP receptor, termed P2Y2-R. This
receptor internalizes into the cell via clathrin coated pits
upon agonist stimulation. Many viruses have evolved
mechanisms and escape from clathrin coated vesicles via a
process termed endosomolysis. Preliminary studies in
non-polarized cells have documented that either bi-specif-
ic monoclonal antibodies directed towards engineered epi-
topes into the external domain of P2Y2-R or modifications
of the native ligand (BiotinUTP) to direct vectors to
P2Y2-R can produce efficient gene transfer via this path-
way (19). More importantly, vector internalization and
gene transfer can also be achieved when P2Y2-R is
expressed in the apical membrane of WD cells. Targeting
through this approach offers several attractive features,
including a wide versatility with respect to the targeting
molecules themselves, e.g., antibodies, peptides, or modi-
fied ligands, and the ability to link the targeting molecule
to a wide variety of vectors, including plasmids, adenoviral,
AAV, and lentiviral vectors.
Can we select a preferred vector now? This would be prema-
ture. A nonviral vector might be preferable because of the
simplicity of the system, but a viral vector, if it were suffi-
ciently safe and efficient, could be a viable alternative. It is
likely that we will see a series of both types of vectors devel-
oped and used clinically. For example, it is possible that
host modification or vector lumenal targeting will become
a reality relatively rapidly, and that “high-capacity” aden-
oviral vectors, because of their proven ability to express in
airway epithelial cells, their relative safety, and the transient
nature of their expression, would be optimal for new stud-
ies of safety and efficacy. In the long term, it would appear
reasonable that for a genetic disease like CF, integrative
gene transfer will be preferable. Thus, it appears wise to
continue the development of lentiviral vectors, both HIV
(20) and non-human (21), and AAV vectors for this use.
The future. It is clear from analysis of the data describing
gene-transfer efficiency from the reported clinical studies
that an order or two of magnitude increase in efficiency will
be required for gene transfer to be therapeutically relevant
in CF. The good news is that all of the previous work has in
principle identified the hurdles that must be cleared prior
to initiation of novel strategies in man. For example, the
WD cultures, freshly excised explant cultures, and bioelec-
tric and expression studies in the mouse nose (but not infec-
tion phenotype in the lung) appear to be accurate models
for predicting efficacy in man in vivo. Further, although
there have been questions about its relevance, it does appear
that the nose as a first approximation is a good model for
lower airways gene transfer in man. Thus, the trial designs
in the nose that have been generally agreed upon, i.e., dou-
ble-blind placebo-controlled studies using nasal PD proto-
cols designed to measure basal Na+ transport and Cl– trans-
port, coupled to molecular and morphologic studies with
a spectrum of sensitivities, appear to offer a rigorous way to
assess the efficacy of a new strategy before initiating more
difficult studies in the lung.
A challenge for lung gene transfer, like other forms of
CF lung therapy, will be the initial trial design to meas-
ure efficacy. Here again, much progress has been made.
In the context of exploring drug therapy to treat the
initiating cause of disease, trial designs have been
explored to assess the ability of novel therapies to pro-
tect the lung against disease. Important analyses of the
required sample sizes for these studies as a function of
patient age have also been recently reported, and
healthy discussions on surrogate markers in the lung
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are ongoing (22). Thus, one can be optimistic that
when we develop strategies that promote routinely
between 10% and 100% gene-transfer efficiency in
human airways, we will be smart enough not to miss
the clinical benefits of gene transfer in CF patients.
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